|1.||Kaverina, N V: 4 articles (01/2007 - 03/2002)|
|2.||Popova, E P: 3 articles (01/2007 - 01/2003)|
|3.||Vititnova, M B: 2 articles (01/2010 - 03/2002)|
|4.||Kryzhanovskiĭ, S A: 2 articles (01/2010 - 03/2002)|
|5.||Lyskovtsev, V V: 2 articles (01/2007 - 01/2003)|
|6.||Stoliaruk, V N: 1 article (01/2010)|
|7.||Tsorin, I B: 1 article (01/2010)|
|8.||Chichkanov, G G: 1 article (03/2003)|
01/01/2010 - "When administered to cats with vagotonic atrial fibrillation afobasol (7.5 mg/kg v/v) exhibited anti-arrhythmic activity at least as high as that of class 1 and III anti-arrhythmic agents (etacisin and cardiocyclide respectively) (Vaughan Williams classification). "
01/01/2007 - "Cardiocyclide was injected in a dose of 2.5-5.0 mg/kg; nibentan, 0.25 mg/kg; and sotalol, 2.5 mg/kg. Cardiocyclide was found to prevent vagotonic atrial fibrillation in 80% of cases; under vagal stimulation this drug maintained the electrophysiological attributes and exhibited the frequency-independent action inherent in this agent. "
01/01/2007 - "The electrophysiological properties of cardiocyclide, nibentan and sotalol and their efficacy on a model of atrial fibrillation were compared in experiments in anaesthetized dogs. "
01/01/2007 - "[Comparative study of the electrophysiological properties of class iii medicinals (cardiocyclide, nibentan, sotalol) and evaluation of their efficacy in atrial fibrillation produced by auricular and vagal stimulation]."
|2.||Myocardial Ischemia (Ischemic Heart Diseases)
01/01/2003 - "Electrophysiological mechanisms of the action of cardiocyclide, nibentan, and sotalol--antiarrhythmic agents of class III--was studied in dogs with experimental myocardial infarction induced by a two-step occlusion of the coronary artery. "
01/01/2003 - "[Comparative study of electrophysiological mechanisms of anti-arrhythmia III class agents, cardiocyclide, nibentan, and sotalol during experimental myocardial infarction and sympathetic stimulation]."
|1.||Sotalol (Sotalol Hydrochloride)
|2.||nibentan (HE 11)